Role of glomerular filtration rate in controlling blood pressure early in diabetes

Hypertension

Volumn 52, Issue 2, 2008, Pages 188-194

  Brands, Michael W ^a   Labazi, Hicham ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; NITRIC OXIDE; SODIUM;

ARTERIAL PRESSURE; BLOOD PRESSURE REGULATION; DIABETES MELLITUS; DISEASE ASSOCIATION; GLOMERULUS FILTRATION RATE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM BALANCE; ADAPTATION; ANIMAL; BLOOD PRESSURE MEASUREMENT; DIABETIC NEPHROPATHY; EARLY DIAGNOSIS; FEMALE; HOSPITALIZATION; MALE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; URINE;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; BLOOD PRESSURE DETERMINATION; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; EARLY DIAGNOSIS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; MALE; RATS; RENIN-ANGIOTENSIN SYSTEM; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SODIUM;

EID: 49849106115     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.107.090647     Document Type: Review

References (84)

1. Guyton AC, Coleman TG. Quantitative analysis of the pathophysiology of hypertension. Circ Res. 1969;24:1-19.
2. Borst JGG, Borst-De Geus A. Hypertension explained by Starling's theory of circulatory homeostasis. Lancet. 1963;1:677-682.
3. Hall JE, Guyton AC, Brands MW. Pressure-volume regulation in hypertension. Kidney Int. 1996;49(suppl 55):S-35-S-41.
4. Poulsen PL, Juhl B, Ebbehoj E, Klein F, Christiansen C, Mogensen CE. Elevated ambulatory blood pressure in microalbuminuric IDDM patients is inversely associated with renal plasma flow. A compensatory mechanism? Diabetes Care. 1997;20:429-432.
5. Hall JE, Guyton AC, Smith MJ Jr, Coleman TG. Blood pressure and renal function during chronic changes in sodium intake: role of angiotensin. Am J Physiol. 1980;239:F271-F280.
6. Hall JE, Mizelle HL, Brands MW, Hildebrandt DA. Pressure natriuresis and angiotensin II in reduced kidney mass, salt-induced hypertension. Am J Physiol. 1992;262:R61-R71.
7. Fitzgerald SM, Brands MW. Nitric oxide may be required to prevent hypertension at the onset of diabetes. Am J Physiol Endocrinol Metab. 2000;279:E762-E768.
8. Brands MW, Fitzgerald SM, Hewitt WH, Hailman AE. Decreased cardiac output at the onset of diabetes: renal mechanisms and peripheral vaso-constriction. Am J Physiol. 2000;278:E917-E924.
9. Brands MW, Fleming C, Bell TD, Sturgis LC, Janardhanan R, Labazi H. Lack of blood pressure salt-sensitivity supports afferent arteriolar action of nitric oxide in Type I diabetes. Clin Expr Pharm Physiol. 2007;34: 475-479.
10. Kikkawa R, Kitamura E, Fujiwara Y, Haneda M, Shigeta Y. Biphasic alteration of renin-angiotensin-aldosterone system in streptozotocin-diabetic rats. Ren Physiol. 1986;9:187-192.
11. Rojas M, Bell TD, Sturgis LC, Janardhanan R, Fleming C, Brands MW. Blood pressure control early in diabetes requires a balance between glomerular filtration rate and the renin-angiotensin system. Am J Hypertens. 2006;19:1249-1255.
12. Miller JA, Floras JS, Zinman B, Skorecki KL, Logan AG. Effect of hyperglycemia on arterial pressure, plasma renin activity, and renal function in early diabetes. Clinical Science. 1996;90:189-195.
13. Brands MW, Cloud LJ. Control of arterial pressure by angiotensin II and nitric oxide at the onset of diabetes. Am J Hypertens. 2003;16:600-603.
14. Cassis LA. Downregulation of the renin-angiotensin system in streptozotocin-diabetic rats Am J Physiol. 1992;262:E105-E109.
15. Kalinyak JE, Sechi LA, Griffin CA, Don BR, Tavangar K, Kraemer FB, Huffman AR, Schambelan M. The renin-angiotensin system in streptozotocin-induced diabetes mellitus in the rat. J Am Soc Nephrol. 1993;4:1337-1345.
16. Price DA, Porter LE, Gordon M, Fisher ND, De'Oliveira JM, Laffei LM, Passan DR, Williams GH, Hollenberg NK. The paradox of the low-renin state in diabetic nephropathy. J Am Soc Nephrol. 1999;10:2382-2391.
17. Vallon V, Wead LM, Blantz RC. Renal heirtodynamics and plasma and kidney angiotensin II in established diabetes mellitus in rats: effect of sodium and salt restriction. J Am Soc Nephrol. 1995;5:1761-1767.
18. Kang JJ, Toma I, Sipos A, Meer EJ, Vargas SL, Peti-Peterdi J. The collecting duct is the major source of prorenin in diabetes. Hypertension. 2008;51:1567-1604.
19. Singh R, Singh AK, Leehey DJ. A novel mechanism for angiotensin II formation in streptozotocin-diabetic rat glomeruli. Am J Physiol Renal Physiol. 2005;288:F1183-F1190.
20. Carey RM, Siragy HM. The intrarenal renin-angiotensin system and diabetic nephropathy. Trends Endocrinol Metab. 2003;14:274-281.
21. Hollenberg NK, Price DA, Fisher ND, Lansang MC, Perkins B, Gordon MS, Williams GH, Laffel LM. Glomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus. Kidney Int. 2003;63:172-178.
22. Thomson SC, Deng A, Bao D, Satriano J, Blantz RC, Vallon V. Omithine decarboxylase. kidney size, and the tubular hypothesis of glomerular hyperfiltration in experimental diabetes. J Clin Invest. 2001;107:217-224.
23. Brands MW, Bell TD, Gibson B. Nitric oxide may prevent hypertension early in diabetes by counteracting renal actions of superoxide. Hypertension. 2004;43:57-63.
24. Dzielak DJ. The immune system and hypertension. Hypertension. 1992; 19:I36-I44.
25. Norman RA Jr, Galloway PG, Dzielak DJ, Huang M. Mechanisms of partial renal infarct hypertension. J Hypertens. 1988;6:397-403.
26. Goncalves AR, Fujihara CK, Mattar AL, Malheiros DM, Noronha Ide L, de Nucci G, Zatz R. Renal expression of COX-2, ANG II, and AT1 receptor in remnant kidney: strong renoproteclion by therapy with losartan and a nonsteroidal anti-inflammatory. Am J Physiol Renal Physiol. 2004;286:F945-F954.
27. Fujihara CK, Antunes GR, Mattar AL, Andreoli N, Malheiros DM, Noronha IL, Zatz R. Cyclooxygenase-2 (COX-2) inhibition limits abnormal COX-2 expression and progressive injury in the remnant kidney. Kidney Int. 2003;64:2172-2181.
28. Griffin KA, Picken M, Bidani AK. Method of renal mass reduction is a critical modulator of subsequent hypertension and glomerular injury. J Am Soc Nephrol. 1994;4:2023-2031.
29. Chen S, Yuan C, Schooley JF Jr, Haddy FJ, Pamnani MB. A consistent model of insulin-dependent diabetes mellitus hypertension. Am J Hypertens. 1992;5:671-680.
30. Mattar AL, Fujihara CK, Ribeiro MO, De Nucci G, Zatz R. Renal effects of acute and chronic nitric oxide inhibition in experimental diabetes. Nephron. 1996;74:136-143.
31. Veelken R, Hilgers KF, Mariner A, Haas A, Bohmer KP, Sterzel RB. Nitric oxide synthase isoforms and glomerular hyperfiltration in early diabetic nephropathy. J Am Soc Nephrol. 2000;11:71-79.
32. Tolins JP, Shultz PJ, Raij L, Brown DM, Mauer SM. Abnormal renal hemodynamic response to reduced renal perfusion pressure in diabetic rats: role of NO. Am J Physiol 1993;265:F886-F895.
33. Komers R, Lindsley JN, Oyama TT, Allison KM, Anderson S. Role of neuronal nitric oxide synthase (NOS1) in the pathogenesis of renal hemodynamic changes in diabetes. Am J Physiol Renal Physiol. 2000;279: F573-F583.
34. Ito A, Uriu K, Inada Y, Qie YL, Takagi I, Ikeda M, Hashimoto O, Suzuka K, Eto S, Tanaka Y, Kaizu K. Inhibition of neuronal nitric oxide synthase ameliorates renal hyperfiltration in streptozotocin-induced diabetic rat. J Lab Clin Med. 2001;138:177-185.
35. Choi KC, Lee SC, Kim SW, Kim NH, Lee JU, Kang YJ. Role of nitric oxide in the pathogenesis of diabetic nephropathy in streptozotocin-induced diabetic rats. Korean J Intern Med. 1999;14:32-41.
36. Thomson SC, Deng A, Komine N, Hammes JS, Blantz RC, Gabbai FB. Early diabetes as a model for testing the regulation of juxtaglomerular NOS I. Am J Physiol Renal Physiol. 2004;287:F732-F738.
37. Komers R, Lindsley JN, Oyama TT, Anderson S. Effects of long-term inhibition of neuronal nitric oxide synthase (NOS1) in uninephrectomized diabetic rats. Nitric Oxide. 2004;11:147-155.
38. Pieper GM. Review of alterations in endothelial nitric oxide production in diabetes. Hypertension. 1998;31:1047-1060.
39. Keynan S, Hirshberg B, Levin-Iaina N, Wexler ID, Dahan R, Reinhartz E, Ovadia H, Wollman Y, Chernihovskey T, Iaina A, Raz I. Renal nitric oxide production during the early phase of experimental diabetes mellitus. Kidney Int. 2000;58:740-747.
40. Schwartz D, Schwartz IF, Blantz RC. An analysis of renal nitric oxide contribution to hyperfiltration in diabetic rats. J Lab Clin Med. 2001;137:107-114.
41. Ishii N, Patel KP, Lane PH, Taylor T, Bian K, Murad F, Pollock JS, Carmines PK. Nitric oxide synthesis and oxidative stress in the renal cortex of rats with diabetes mellitus. J Am Soc Nephrol. 2001;12:1630-1639.
42. Welch WJ, Tojo A, Lee J-U, Rang DG, Schnackenberg CG, Wilcox CS. Nitric oxide synthase in the JGA of the SHR: expression and role in tubuloglomerular feedback. Am J Physiol. 1999;277:F130-F138.
43. Ollerstam A, Persson AE. Macula densa neuronal nitric oxide synthase. Cardiovasc Res. 2002;56:189-196.
44. Kovacs G, Komlosi P, Fuson A, Peti-Peterdi J, Rosivall L, Bell PD. Neuronal nitric oxide synthase: its role and regulation in macula densa cells, J Am Soc Nephrol. 2003;14:2475-2483.
45. Schnermann J, Levine DZ. Paracrine factors in tubuloglomerular feedback: adenosine, ATP, and nitric oxide. Annu Rev Physiol. 2003;65:501-529.
46. Thorup C, Persson AEG. Macula densa derived nitric oxide in regulation of glomerular capillary pressure. Kidney Int. 1996;49:430-436.
47. Wang H, Carretero OA, Garvin JL. Nitric oxide produced by THAL nitric oxide synthase inhibits TGF. Hypertension. 2002;39:662-666.
48. Braam B, Turkstra E, Koomans HA. Concerted actions of renal endothelial and macula densa NO systems in the maintenance of extracellular fluid volume. Acta Physiol Scand. 2000;168:125-132.
49. Ichihara A, Navar LG. Neuronal NOS contributes to biphasic autoregulatory response during enhanced TGF activity. Am J Physiol. 1999;277:F113-F120.
50. Thomson SC, Deng A. Cyclic GMP mediates influence of macula densa nitric oxide over tubuloglomerular feedback. Kidney Blood Press Res. 2003;26:10-18.
51. Wilcox CS, Welch WJ. Interaction between nitric oxide and oxygen radicals in regulation of tubuloglomerular feedback. Acta Physiol Scand. 2000;168:119-124.
52. Blantz RC, Deng A, Lortie M, Munger K, Vallon V, Gabbai FB, Thomson SC. The complex role of nitric oxide in the regulation of glomerular ultrafiltration. Kidney Int. 2002;61:782-785.
53. Thorup C, Persson AE. Inhibition of locally produced nitric oxide resets tubuloglomerular feedback mechanism. Am J Physiol. 1994;267:F606-F611.
54. Bidani AK, Hacioglu R, Abu-Amarah I, Williamson GA, Loutzenhiser R, Griffin KA. "Step" vs. "dynamic" autoregulation: implications for susceptibility to hypertensive injury. Am J Physiol Renal Physiol. 2003;285: F113-F120.
55. DiBona GF, Sawin LL. Effect of renal denervation on dynamic autoregulation of renal blood flow. Am J Physiol Renal Physiol. 2004;286:F1209-F1218.
56. Loutzenhiser R, Griffin K, Williamson G, Bidani A. Renal autoregulation: new perspectives regarding the protective and regulatory roles of the underlying mechanisms. Am J Physiol Regul Integr Comp Physiol. 2006;290:R1153- R1167.
57. Wang X, Cupples WA. Interaction between nitric oxide and renal myogenic autoregulation in normotensive and hypertensive rats. Can J Physiol Pharmacol. 2001;79:238-245.
58. Bell TD, DiBona GF, Wang Y, Brands MW. Mechanisms for renal blood flow control early in diabetes as revealed by chronic flow measurement and transfer function analysis. J Am Soc Nephrol. 2006;17:2184-2192.
59. Bell TD, Brands MW Role of nitric oxide in renal blood flow control during diabetes as revealed by continuous measurement [abstract P79]. Hypertension. 2006;48:e60.
60. Sugimoto HS, Matsuda K, Kushiro M, Hayashi M, Hiragushi Y, Wada K, Makino JH. Increased expression of endothelial cell nitric oxide synthase (ecNOS) in afferent and glomerular endothelial cells is involved in glomerular hyperfiltration of diabetic nephropathy. Diabetologia. 1998;41:1426-1434.
61. De Vriese AS, Stoenoiu MS, Elger M, Devuyst O, Vanholder R, Kriz W, Lameire NH. Diabetes-induced microvascular dysfunction in the hydronephrotic kidney: role of nitric oxide. Kidney Int. 2001;60:202-210.
62. Hiragushi K, Sugimoto H, Shikata K, Yamashita T, Miyatake N, Shikata Y, Wada J, Kumagai I, Fukushima M, Makino H. Nitric oxide system is involved in glomerular hyperfiltration in Japanese normo- and micro-albuminuric patients with type 2 diabetes. Diabetes Res Clin Pract. 2001;53:149-159.
63. Zhao HJ, Wang S, Cheng H, Zhang MZ, Takahashi T, Fogo AB, Breyer MD, Harris RC. Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice. J Am Soc Nephrol. 2006;17:2664-2669.
64. Vallon V, Richter K, Blantz RC, Thomson S, Osswald H. Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption. J Am Soc Nephrol. 1999;10:2569-2576.
65. Thomson SC, Vallon V, Blantz RC. Kidney function in early diabetes: the tubular hypothesis of glomerular filtration. Am J Physiol Renal Physiol. 2004;286:F8-F15.
66. Leyssac PP, Holstein-Rathlou NH, Skott O. Renal blood flow, early distal sodium, and plasma renin concentrations during osmotic diuresis. Am J Physiol Regul Integr Comp Physiol. 2000;279:R1268-R1276.
67. Woods LL, Mizelle HL, Hall JE. Control of renal hemodynamics in hyperglycemia: possible role of tubuloglomerular feedback. Am J Physiol. 1987;252:F65-F71.
68. Faulhaber-Walter R, Chen L, Oppermann M, Kim SM, Huang Y, Hiramatsu N, Mizel D, Kajiyama H, Zerfas P, Briggs JP, Kopp JB, Schnermann J. Lack of Al adenosine receptors augments diabetic hyperfiltration and glomerular injury. J Am Soc Nephrol. 2008;19:722-730.
69. Pollock CA, Lawrence JR, Field MJ. Tubular sodium handling and tubuloglomerular feedback in experimental diabetes mellitus. Am J Physiol. 1991;260:F946-F952.
70. Navar LG, Ichihara A, Chin SY, Imig JD. Nitric oxide-angiotensin II interactions in angiotensin II-dependent hypertension. Acta Physiol Scand. 2000;168:139-147.
71. Ito S, Arima S, Ren YL, Juncos LA, Carretero OA. Endothelium-derived relaxing factor/nitric oxide modulates angiotensin II action in the isolated microperfused rabbit afferent but not efferent arteriole. J Clin Invest. 1993;91:2012-2019.
72. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735-2752.
73. Haffner SM. Risk constellations in patients with the metabolic syndrome: epidemiology, diagnosis, and treatment patterns. Am J Med. 2006;119:S3-S9.
74. Lastra G, Manrique C, Sowers JR. Obesity, cardiometabolic syndrome, and chronic kidney disease: the weight of the evidence. Adv Chronic Kidney Dis. 2006;13:365-373.
75. Hall JE, Brands MW, Dixon WN, Smith MJ Jr. Obesity-induced hypertension. Renal function and systemic hemodynamics. Hypertension. 1993;22:292-299.
76. Kirpichnikov D, Sowers JR. Diabetes mellitus and diabetes-associated vascular disease. Trends Endocrinol Metab. 2001;12:225-230.
77. Izzo JL Jr. Prehypertension: demographics, pathophysiology, and treatment. Curr Hypertens Rep. 2007;9:264-268.
78. Deedwania PC, Schmieder R. Angiotensin receptor blockers: Cardiovascular protection in the metabolic syndrome. J Renin Angiolensin Aldosterone Syst. 2006;7(suppl 1):S12-S18.
79. Sharma AM. Is there a rationale for angiotensin blockade in the management of obesity hypertension? Hypertension. 2004;44:12-19.
80. Steinberg HO, Chaker H, Learning R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. J Clin Invest. 1996;97:2601-2610.
81. Dobrian AD, Davies MJ, Schriver SD, Lauterio TJ, Prewitt RL. Oxidative stress in a rat model of obesity-induced hypertension. Hypertension. 2001;37:554-560.
82. Whaley-Connell A, Pavey BS, Afroze A, Bakris GL. Obesity and insulin resistance as risk factors for chronic kidney disease. J Cardiometab Syndr. 2006;1:209-214.
83. Sharma V, McNeill JH. The etiology of hypertension in the metabolic syndrome part three: the regulation and dysregulation of blood pressure. Curr Vasc Pharmacol. 2006;4:321-348.
84. Bigazzi R, Bianchi S. Insulin resistance, metabolic syndrome and endothelial dysfunction. J Nephrol. 2007;20:10-14.